Synthesis of Radiolabeled and Stable‐Isotope Labeled Deucravacitinib (BMS‐986165)
Journal of Labelled Compounds and Radiopharmaceuticals · 2025
DOI: 10.1002/jlcr.4156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von John A Brailsford und 2 weiteren Autor:innen. Beteiligte Einrichtung: Discovery and Development Sciences - Radiochemistry, Bristol Myers Squibb, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors. Die Arbeit nennt 7 Literaturangaben. Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb Canada.
Abstract (Originalsprache)
Deucravacitinib (BMS‐986165) is a small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2) currently approved for the treatment of moderate to severe plaque psoriasis. Tyrosine kinase 2 (TYK2) is a member of the Janus (JAK) family of non‐receptor kinases that modulate the production of inflammatory cytokines. The synthesis of 14 C‐radiolabeled and stable‐isotope labeled variants of deucravacitinib is described in this publication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery and Development Sciences - Radiochemistry, Bristol Myers Squibb, Princeton, New Jersey, USA.
ORCID-Profile: John A Brailsford, Kai Cao
Förderung
- Bristol Myers Squibb
- Bristol-Myers Squibb Canada
Zitieren
APA
Brailsford, J. A., Cao, K., & Bonacorsi, S. J. (2025). Synthesis of Radiolabeled and Stable‐Isotope Labeled Deucravacitinib (BMS‐986165). Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4156
Vancouver
Brailsford JA, Cao K, Bonacorsi SJ. Synthesis of Radiolabeled and Stable‐Isotope Labeled Deucravacitinib (BMS‐986165). Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4156
BibTeX
@article{Brailsford2025,
author = {Brailsford, John A and Cao, Kai and Bonacorsi, Samuel J},
title = {Synthesis of Radiolabeled and Stable‐Isotope Labeled Deucravacitinib (BMS‐986165)},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2025},
doi = {10.1002/jlcr.4156}
}
EUVIMED